Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).

Abstract

This report describes some experimental and clinical studies showing the following: (1) in animals under protection of mesna the dose of ifosfamide (Ifo) can be increased significantly; (2) fractionated administration of Ifo, cyclophosphamide (CPA), or the stabilized metabolite of cyclophosphamide (ASTA Z 7557) is less toxic than single push-injection of the same total daily dose and therapeutically more effective; and (3) in humans under the protection of mesna the continuous infusions of ifosfamide over 5 days leads to an increase of the MTD compared with single daily short-term infusion and responses in some solid tumors, e.g., soft tissue sarcomas.

• Authors: H O Klein, P D Wickramanayake, E Christian, C Coerper
• Journal: Cancer (Cancer) Vol. 54 Issue 6 Suppl Pg. 1193-203 (Sep 15 1984) ISSN: 0008-543X [Print] United States
• PMID: 6432305 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Asta Z 7557
• Cyclophosphamide
• Mesna
• Ifosfamide

Topics

• Animals
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage, analogs & derivatives, toxicity)
• Humans
• Ifosfamide (administration & dosage, toxicity)
• Infusions, Parenteral
• Kidney (drug effects)
• Lethal Dose 50
• Male
• Mesna (administration & dosage)
• Mice
• Mice, Inbred Strains
• Middle Aged
• Neoplasms (drug therapy)